Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Medicine & Life Sciences

• Platinum 100%
• Non-Small Cell Lung Carcinoma 85%
• Neoplasms 30%
• Therapeutics 15%
• Random Allocation 5%
• Survival 4%
• atezolizumab 4%
• Immunogenic Cell Death 4%
• Histology 4%
• pembrolizumab 4%
• Nivolumab 3%
• Population 3%
• Safety 3%
• Docetaxel 3%
• Leukopenia 3%
• Skin Diseases 2%
• Practice Guidelines 2%
• Intention 2%
• Anemia 2%
• Pneumonia 2%
• Cell Survival 2%
• Research Personnel 2%
• Thorax 1%
• Hemorrhage 1%
• Equipment and Supplies 1%
• Drug Therapy 1%
• Lung 1%
• Infections 1%